

Atopic dermatitis

1.

Description	Pro-sensitizing effect on human skin
Biological model	Human keratinocyte cell line (HACaT)
Endpoint	TSLP release
Method	ELISA/EIA
Positive control	LPS
Test compound	Topycal/Systemic

2.

Description	Sensitizing potential on antigen presenting cells
Biological model	Primary human monocytoïd dendritic cells
Endpoint:	membrane CD80/CD86 modulation
Method	flow cytometry
Positive control	LPS
Control for efficacy	Dexametasone
Test compound	Topical/Systemic

3.

Description	Pro-inflammatory effect
Biological model	human PBMC
Endpoint:	TNF-alpha IL-1-beta
Method:	ELISA/EIA
Positive control	LPS
Control for efficacy	Dexametasone/hydroxypropyl chitosan
Test compound	Topical/Systemic

4.

Description	Th2 polarization of lymphocytes
Biological model	Primary human T lymphocytes
Endpoint	a) IL-4 release b) IL-5 release c) IL-13 release d) IL-31 release
Method	ELISA/EIA
Positive control	anti-CD28/anti-CD3
Control for efficacy	Dexametasone
Test compound	Topical/Systemic

5.

Description	Basophil degranulation (itching)
Biological model	human-IgE transfected rat basophilic leukemia cell line (RBL-SX38)
Endpoint:	Hexosaminidase
Method:	ELISA/EIA
Positive control	anti-IgE
Control for efficacy	Hyaluronic acid
Test compound	Topical/Systemic